ACAD
28.01
+0.16
+0.57%
AEMD
2.06
+0.01
+0.49%
APRI
1.04
+0.01
+0.97%
ARNA
1.34
+0.01
+0.75%
ATEC
2.09
+0.02
+0.97%
CNAT
5.3
+0.08
+1.53%
CRXM
0.121
-0.049
-28.824%
CYTX
0.96
-0.01
-1.03%
DXCM
68.85
+1.19
+1.76%
GNMK
13.21
+0.2
+1.54%
HALO
12.79
-0.12
-0.93%
ILMN
174.92
-2.09
-1.18%
INNV
0.108
+0.01
+9.6939%
INO
7.09
-0.08
-1.12%
ISCO
1.64
-0.09
-5.20%
ISIS
57.56
0.00
0.00%
LGND
113.44
-0.37
-0.33%
LPTN
2.93
0.00
0.00%
MBVX
1.71
-0.09
-5.00%
MEIP
1.64
+0.02
+1.23%
MNOV
5.65
+0.14
+2.54%
MRTX
3.65
0.00
0.00%
MSTX
0.131
0.00
0.00%
NBIX
53.64
+0.85
+1.61%
NUVA
71.54
+0.66
+0.93%
ONCS
0.9
-0.05
-5.14%
ONVO
2.81
+0.02
+0.72%
OREX
3.03
-0.12
-3.81%
OTIC
13.25
-0.15
-1.12%
QDEL
24.57
+0.16
+0.66%
RCPT
231.96
0.00
0.00%
RGLS
1.375
-0.075
-5.172%
RMD
69.51
+1.11
+1.62%
SCIE
0.001
0.00
0.00%
SPHS
2.48
-0.01
-0.40%
SRNE
1.725
+0.15
+9.524%
TROV
0.776
-0.025
-3.121%
VICL
2.29
+0.02
+0.88%
VOLC
18
0.00
0.00%
ZGNX
13.1
-0.25
-1.87%
ACAD
28.01
+0.16
+0.57%
AEMD
2.06
+0.01
+0.49%
APRI
1.04
+0.01
+0.97%
ARNA
1.34
+0.01
+0.75%
ATEC
2.09
+0.02
+0.97%
CNAT
5.3
+0.08
+1.53%
CRXM
0.121
-0.049
-28.824%
CYTX
0.96
-0.01
-1.03%
DXCM
68.85
+1.19
+1.76%
GNMK
13.21
+0.2
+1.54%
HALO
12.79
-0.12
-0.93%
ILMN
174.92
-2.09
-1.18%
INNV
0.108
+0.01
+9.6939%
INO
7.09
-0.08
-1.12%
ISCO
1.64
-0.09
-5.20%
ISIS
57.56
0.00
0.00%
LGND
113.44
-0.37
-0.33%
LPTN
2.93
0.00
0.00%
MBVX
1.71
-0.09
-5.00%
MEIP
1.64
+0.02
+1.23%
MNOV
5.65
+0.14
+2.54%
MRTX
3.65
0.00
0.00%
MSTX
0.131
0.00
0.00%
NBIX
53.64
+0.85
+1.61%
NUVA
71.54
+0.66
+0.93%
ONCS
0.9
-0.05
-5.14%
ONVO
2.81
+0.02
+0.72%
OREX
3.03
-0.12
-3.81%
OTIC
13.25
-0.15
-1.12%
QDEL
24.57
+0.16
+0.66%
RCPT
231.96
0.00
0.00%
RGLS
1.375
-0.075
-5.172%
RMD
69.51
+1.11
+1.62%
SCIE
0.001
0.00
0.00%
SPHS
2.48
-0.01
-0.40%
SRNE
1.725
+0.15
+9.524%
TROV
0.776
-0.025
-3.121%
VICL
2.29
+0.02
+0.88%
VOLC
18
0.00
0.00%
ZGNX
13.1
-0.25
-1.87%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.

Be Sociable, Share!